Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China

European Journal of Clinical Pharmacology

Volumn 70, Issue 8, 2014, Pages 941-946

  Chang, Ying ^a   Yang, Li Ya ^a   Zhang, Meng Chao ^a   Liu, Song Yan ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Blood concentration; Epilepsy; Gene polymorphism; Lamotrigine; UGT1A4

Indexed keywords

ANTICONVULSIVE AGENT; BILIRUBIN GLUCURONOSIDE GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; LAMOTRIGINE; TRIAZINE DERIVATIVE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; CLINICAL TRIAL; EPILEPSY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; EPILEPSY; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; TRIAZINES;

EID: 84905123903     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1690-1     Document Type: Article

References (27)

1. Pellock JM (2007) Overview of lamotrigine and the new antiepileptic drugs: the challenge. J Child Neurol 12(1):S48-S52
2. Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45:1061-1075 (Pubitemid 44631387)
3. Milovanovic JR, Jankovic SM (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47:752-760
4. Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK (2008) Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 48:455-463 (Pubitemid 351389112)
5. Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Dominguez-Gil A, Garcia MJ (2008) Population pharmacokinetics of lamotrigine with data fromtherapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 30:483-489
6. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95:1-8
7. Franciotta D, Kwan P, Perucca E (2009) Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2:144-149
8. Benoit-Binomics MO, Adam JP, Bernard O et al (2009) A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics 19(12):945-954
9. Yea SS, Lee SS, KimWY, Liu KH, Kim H, Shon JH, Cha IJ, Shin JG (2008) Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 30(1):23-34 (Pubitemid 351161095)
10. Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J (2006) Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 27(7):717
11. Hakooz N, Alzubiedi S, YousefAM, Arafat T, Dajani R, Ababneh N, Ismail S (2012) UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population. Mol Biol Rep 39(7):7763-7768
12. Engel J Jr (2001) A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 42(6):796-803
13. Engel J Jr, Van Ness PC, Rasmussen TB, Ojemann LM (1993) Outcome with respect to epileptic seizures. In: Engel J Jr (ed) Surgical treatment of the epilepsies, 2nd edn. Raven Press, New York, pp 609-621
14. Rowland A, Elliot DJ, Williams JA et al (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotriginevalproic acid interation. Drug Metab Dispos 34:1055-1062 (Pubitemid 43763765)
15. Hiller A, Nguyen N, Strassburg CP et al (1999) Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 27(5):605-612 (Pubitemid 29214473)
16. Posner J, Cohen AF, Land G et al (1989) The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinemia (Gilbert's syndrome). Br J Clin Pharmacol 28:117-120 (Pubitemid 19195674)
17. Kubota T, Lewis BC, Elliot DJ et al (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72(4):1054-1062 (Pubitemid 47481428)
18. Singkham N, Towanabut S, Lertkachatarn S et al (2013) Influence of the UGT 2B7-161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 69(6):1285-1291
19. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Sttassburg CP (2004) Variation of hepatic glucuronidation:novel functional polymorphisms of the UDP glucuronosyltransferase UGT1A4. Hepatology 39(4):970-977 (Pubitemid 38428936)
20. Wiener D, Doerge DR, Fang JL et al (2004) Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol (NNAL) in human liver:importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32(1):72-79 (Pubitemid 38112538)
21. Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP- glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 33(5):672-675 (Pubitemid 40593882)
22. Saeki M, Saito Y, Jinno H et al (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20(2):144-151
23. Erickson-Ridout KK, Sun D, Lazarus P (2012) Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms. Pharmacogenet Genomics 22:561-576
24. Ghotbi R, Mannheimer B, Aklillu E, Suda A et al (2010) Carriers of the UGT1A4 142 T>G gene variant are predisposed to reduced olanzapine exposure - an impact similar to male gender or smoking in schizophrenic patients. Eur J Pharmacol 66:465-474
25. Sun D, Chen G, Dellinger RW, Duncan K et al (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Can Res 8(R50):1-11
26. Saeki M, Saito Y, Jinno H et al (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20(2):144-151
27. Duan JB, Wainwright MS, Comeron JM et al (2003) Synonymous mutations in the human dopamine receptor D2(DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205-216 (Pubitemid 36204418)